Bayesian methods for the design and analysis of noninferiority trials

被引:17
|
作者
Gamalo-Siebers, Margaret [1 ]
Gao, Aijun [2 ]
Lakshminarayanan, Mani [3 ]
Liu, Guanghan [4 ]
Natanegara, Fanni [5 ]
Railkar, Radha [3 ]
Schmidli, Heinz [6 ]
Song, Guochen [7 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA
[2] InVent Hlth Clin, Princeton, NJ USA
[3] Pfizer Inc, Biotechnol Clin Dev Stat, Collegeville, PA 19426 USA
[4] Merck Sharp & Dohme Corp, N Wales, PA USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Novartis Pharma AG, Basel, Switzerland
[7] Quintiles, Durham, NC USA
关键词
Bayesian inference; clinical trial; meta-analysis; noninferiority; ACTIVE-CONTROL TRIALS; SAMPLE-SIZE CALCULATIONS; NON-INFERIORITY TRIALS; CLINICAL-TRIALS; HISTORICAL INFORMATION; STATISTICAL-METHODS; PLACEBO; PROPORTIONS; COMBINATION; HYPOTHESIS;
D O I
10.1080/10543406.2015.1074920
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The gold standard for evaluating treatment efficacy of a medical product is a placebo-controlled trial. However, when the use of placebo is considered to be unethical or impractical, a viable alternative for evaluating treatment efficacy is through a noninferiority (NI) study where a test treatment is compared to an active control treatment. The minimal objective of such a study is to determine whether the test treatment is superior to placebo. An assumption is made that if the active control treatment remains efficacious, as was observed when it was compared against placebo, then a test treatment that has comparable efficacy with the active control, within a certain range, must also be superior to placebo. Because of this assumption, the design, implementation, and analysis of NI trials present challenges for sponsors and regulators. In designing and analyzing NI trials, substantial historical data are often required on the active control treatment and placebo. Bayesian approaches provide a natural framework for synthesizing the historical data in the form of prior distributions that can effectively be used in design and analysis of a NI clinical trial. Despite a flurry of recent research activities in the area of Bayesian approaches in medical product development, there are still substantial gaps in recognition and acceptance of Bayesian approaches in NI trial design and analysis. The Bayesian Scientific Working Group of the Drug Information Association provides a coordinated effort to target the education and implementation issues on Bayesian approaches for NI trials. In this article, we provide a review of both frequentist and Bayesian approaches in NI trials, and elaborate on the implementation for two common Bayesian methods including hierarchical prior method and meta-analytic-predictive approach. Simulations are conducted to investigate the properties of the Bayesian methods, and some real clinical trial examples are presented for illustration.
引用
收藏
页码:823 / 841
页数:19
相关论文
共 50 条
  • [31] Bayesian methods: a potential path forward for sepsis trials
    Tomlinson, George
    Al-Khafaji, Ali
    Conrad, Steven A.
    Factora, Faith N. F.
    Foster, Debra M.
    Galphin, Claude
    Gunnerson, Kyle J.
    Khan, Sobia
    Kohli-Seth, Roopa
    Mccarthy, Paul
    Meena, Nikhil K.
    Pearl, Ronald G.
    Rachoin, Jean-Sebastien
    Rains, Ronald
    Seneff, Michael
    Tidswell, Mark
    Walker, Paul M.
    Kellum, John A.
    CRITICAL CARE, 2023, 27 (01)
  • [32] Incorporating a companion test into the noninferiority design of medical device trials
    Lu, Nelson T.
    Xu, Yunling
    Yang, Ying
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (01) : 143 - 150
  • [33] Design and analysis of Bayesian adaptive crossover trials for evaluating contact lens safety and efficacy
    Zhang, Quan
    Toubouti, Youssef
    Carlin, Bradley P.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2017, 26 (03) : 1216 - 1236
  • [34] Practical Bayesian design and analysis for drug and device clinical trials
    Hobbs, Brian P.
    Carlin, Bradley P.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2008, 18 (01) : 54 - 80
  • [35] Bayesian design and analysis of external pilot trials for complex interventions
    Wilson, Duncan T.
    Wason, James M. S.
    Brown, Julia
    Farrin, Amanda J.
    Walwyn, Rebecca E. A.
    STATISTICS IN MEDICINE, 2021, 40 (12) : 2877 - 2892
  • [36] Bayesian design and analysis of 2 by 2 factorial clinical trials
    Simon, R
    Freedman, LS
    AMERICAN STATISTICAL ASSOCIATION - 1996 PROCEEDINGS OF THE SECTION ON BAYESIAN STATISTICAL SCIENCE, 1996, : 180 - 185
  • [37] Analysis of two binomial proportions in noninferiority confirmatory trials
    Lakkis, Hassan
    Lakkis, Andrew
    PHARMACEUTICAL STATISTICS, 2024, 23 (02) : 257 - 275
  • [38] Noninferiority Clinical Trials With Binary Outcome: Statistical Methods Used in Practice
    Sidi, Yulia
    Harel, Ofer
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2021, 13 (04): : 476 - 482
  • [39] Rationale for and Methods of Superiority, Noninferiority, or Equivalence Designs in Orthopaedic, Controlled Trials
    Vavken, Patrick
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2011, 469 (09) : 2645 - 2653
  • [40] Blinded Sample Size Recalculation in Noninferiority Trials: A Case Study in Dermatology
    Friede, Tim
    Stammer, Holger
    DRUG INFORMATION JOURNAL, 2010, 44 (05): : 599 - 607